Skip to main content
FDA fast-tracks Sesen Bio's bladder cancer drug
8/10/2018

The FDA granted fast-track status to Sesen Bio's Vicinium, which is in late-stage trials and is being developed as a treatment for patients with BCG-unresponsive high-grade non-muscle invasive bladder cancer.

Full Story: